ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $53.96 and traded as high as $58.94. ProShares Ultra Nasdaq Biotechnology shares last traded at $56.96, with a volume of 16,375 shares.
ProShares Ultra Nasdaq Biotechnology Trading Down 2.3 %
The company has a fifty day moving average of $53.96 and a two-hundred day moving average of $60.13.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently declared a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a dividend of $0.3964 per share. The ex-dividend date of this dividend was Monday, December 23rd. This is an increase from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
An institutional investor recently raised its position in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC boosted its holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,803 shares of the exchange traded fund's stock after acquiring an additional 374 shares during the quarter. Jane Street Group LLC owned about 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 as of its most recent filing with the SEC.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
